Fractyl Health (GUTS) Net Income towards Common Stockholders (2023 - 2026)
Fractyl Health's (GUTS) quarterly Net Income towards Common Stockholders came in at -$26.1 million in Q1 2026, down 10.11% YoY from -$29.1 million in Q1 2025, and up 40.23% on a QoQ basis from -$43.7 million in Q4 2025.
Fractyl Health (GUTS) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$26.1 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 10.11% year-over-year to -$26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$143.4 million (down 60.88% YoY) and the FY2025 annual result came in at -$141.0 million, down 100.13% from the prior year.
- Net Income towards Common Stockholders rose to -$26.1 million in Q1 2026, from -$43.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$5.1 million in Q1 2024 to a low of -$45.6 million in Q3 2025.
- A 4-year average of -$25.5 million and a median of -$23.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 68.71% — and 2025, when it slumped 369.16%.
- Tracing GUTS's Net Income towards Common Stockholders over 4 years: stood at -$23.5 million in 2023, then decreased by 6.21% to -$25.0 million in 2024, then plunged by 75.12% to -$43.7 million in 2025, then soared by 40.23% to -$26.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$26.1 million (Q1 2026), -$43.7 million (Q4 2025), and -$45.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | -18.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.99 Mn |
| Mar 31, 2026 | -26.13 Mn |
| Dec 31, 2025 | -43.73 Mn |
| Sep 30, 2025 | -45.60 Mn |
| Jun 30, 2025 | -27.89 Mn |
| Mar 31, 2025 | -23.74 Mn |
| Dec 31, 2024 | -24.97 Mn |
| Sep 30, 2024 | -23.17 Mn |
| Jun 30, 2024 | -17.23 Mn |
| Mar 31, 2024 | -5.06 Mn |
| Dec 31, 2023 | -23.51 Mn |
| Sep 30, 2023 | -20.08 Mn |
| Jun 30, 2023 | -34.52 Mn |
| Mar 31, 2023 | -16.17 Mn |